Senvest Management LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Senvest Management LLC grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 895,760 shares of the life sciences company’s stock after acquiring an additional 2,990 shares during the quarter. Illumina accounts for approximately 4.1% of Senvest Management LLC’s investment portfolio, making the stock its 8th biggest position. Senvest Management LLC owned about 0.56% of Illumina worth $116,816,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Versant Capital Management Inc increased its stake in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after acquiring an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina during the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in Illumina in the second quarter valued at about $61,000. Finally, Mizuho Securities Co. Ltd. bought a new stake in Illumina during the second quarter worth about $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 2.3 %

Shares of ILMN stock opened at $140.14 on Friday. Illumina, Inc. has a 52-week low of $93.51 and a 52-week high of $156.66. The company has a 50-day simple moving average of $140.61 and a two-hundred day simple moving average of $124.84. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The company has a market capitalization of $22.23 billion, a price-to-earnings ratio of -14.07 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period last year, the business posted $0.33 earnings per share. Illumina’s revenue was down 3.5% on a year-over-year basis. Research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ILMN. Canaccord Genuity Group raised their target price on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a report on Tuesday, November 5th. Morgan Stanley reissued an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, November 12th. Royal Bank of Canada upped their target price on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.